Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Hong Wang, Qingxian He, Guangji Wang, Xiaowei Xu & Haiping Hao. (2018) FXR modulators for enterohepatic and metabolic diseases. Expert Opinion on Therapeutic Patents 28:11, pages 765-782.
Read now
Read now
Danny Issa, Julia Wattacheril & Arun J. Sanyal. (2017) Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Expert Opinion on Drug Safety 16:8, pages 903-913.
Read now
Read now
Articles from other publishers (33)
Fan Zhao, Lun Zhang, Mingchao Qu, Lu Ye, Jiayi Zhang, Yun Yu, Qianqian Huang, Cheng Zhang & Jianqing Wang. (2023) Obeticholic acid alleviates intrauterine growth restriction induced by di-ethyl-hexyl phthalate in pregnant female mice by improving bile acid disorder. Environmental Science and Pollution Research 30:51, pages 110956-110969.
Crossref
Crossref
Lili Xi, Axi Shi, Tiantian Shen, Guoxu Wang, Yuhui Wei & Jingjing Guo. (2023) Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies. Frontiers in Pharmacology 14.
Crossref
Crossref
Zhiqi Feng, Jiehao Xiang, Gang Sun, Hui Liu, Yanyan Wang, Xin Liu, Jin Feng, Qinglong Xu, Xiaoan Wen, Haoliang Yuan, Hongbin Sun & Liang Dai. (2023) Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases. Journal of Medicinal Chemistry 66:11, pages 7331-7354.
Crossref
Crossref
Tong Qin, Xuefeng Gao, Lei Lei, Jing Feng, Wenxuan Zhang, Yuhua Hu, Zhufang Shen, Zhenming Liu, Yi Huan, Song Wu, Jie Xia & Liangren Zhang. (2023) Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease. European Journal of Medicinal Chemistry 252, pages 115307.
Crossref
Crossref
Tiannan Zhou, Huixian Wei & Jinjun Wang. (2023) Research experimental design for the construction and identification of the pGEX-BCKD-E4A recombinant point-mutant plasmid. PLOS ONE 18:2, pages e0279431.
Crossref
Crossref
Beata Kasztelan-Szczerbinska, Anna Rycyk-Bojarzynska, Agnieszka Szczerbinska & Halina Cichoz-Lach. (2023) Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview. Nutrients 15:3, pages 760.
Crossref
Crossref
Moath Refat, Guoqiang Zhang, Abdulaziz Ahmed A.Saad, Salem Baldi, Fang Zheng & Xin'an Wu. (2023) 7, 8-Dihydroxy-4-methyl coumarin alleviates cholestasis via activation of the Farnesoid X receptor in vitro and in vivo. Chemico-Biological Interactions 370, pages 110331.
Crossref
Crossref
Jinying Gu, Qiuyu Wu, Qiuyue Zhang, Qidong You & Lei Wang. (2022) A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. European Journal of Medicinal Chemistry 243, pages 114742.
Crossref
Crossref
Albert P. Li. 2021. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity
41
77
.
Ioannis Evangelakos, Joerg Heeren, Esther Verkade & Folkert Kuipers. (2021) Role of bile acids in inflammatory liver diseases. Seminars in Immunopathology 43:4, pages 577-590.
Crossref
Crossref
Yang Liu, Yongtao Xiao, Shanshan Chen, Xinbei Tian, Weipeng Wang, Ying Wang & Wei Cai. (2021) The Farnesoid X Receptor Agonist Tropifexor Prevents Liver Damage in Parenteral Nutrition-fed Neonatal Piglets. Journal of Pediatric Gastroenterology & Nutrition 73:1, pages e11-e19.
Crossref
Crossref
Junhui Yu, Kui Yang, Jianbao Zheng, Wei Zhao & Xuejun Sun. (2020) Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand. Cancer Gene Therapy 28:6, pages 590-601.
Crossref
Crossref
I. M. Iljinsky & O. M. Tsirulnikova. (2021) Primary biliary cholangitis. Russian Journal of Transplantology and Artificial Organs 23:1, pages 162-170.
Crossref
Crossref
Longying Jiang, Desheng Xiao, Yubin Li, Shuyan Dai, Lingzhi Qu, Xiaojuan Chen, Ming Guo, Hudie Wei & Yongheng Chen. (2021) Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor. Biochemical and Biophysical Research Communications 534, pages 1047-1052.
Crossref
Crossref
Shan Li, Zhengshui Xu, Jing Guo, Jianbao Zheng, Xuejun Sun & Junhui Yu. (2020) Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene. Journal of Cellular and Molecular Medicine 24:24, pages 14549-14560.
Crossref
Crossref
Guoqiang Zhang, Xiaohan Sun, Yuanjie Wen, A'xi Shi, Jianping Zhang, Yuhui Wei & Xin'an Wu. (2020) Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo. European Journal of Pharmacology 885, pages 173498.
Crossref
Crossref
Jiasheng Wu, Su Fang, Wenkai Li, Yifei Li, Yuanyuan Li, Tianming Wang, Li Yang, Shaoyong Liu, Zhengtao Wang & Yueming Ma. (2020) Metabolomics research on the hepatoprotective effect of cultured bear bile powder in α-naphthylisothiocyanate-induced cholestatic mice. Journal of Chromatography B 1153, pages 122269.
Crossref
Crossref
Raquel T Yokoda & Eduardo A Rodriguez. (2020) Review: Pathogenesis of cholestatic liver diseases. World Journal of Hepatology 12:8, pages 423-435.
Crossref
Crossref
Zobair M. Younossi, Maria Stepanova, Pegah Golabi, Robert S. Epstein, Marcie E. Strauss, Fatema Nader & Andrei Racila. (2019) Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis. Journal of Clinical Gastroenterology 53:9, pages 693-698.
Crossref
Crossref
Renchao Dong, Junqiao Wang, Xiaoguang Gao, Changyuan Wang, Kexin Liu, Jingjing Wu, Zhihao Liu, Huijun Sun, Xiaodong Ma & Qiang Meng. (2019) Yangonin protects against estrogen–induced cholestasis in a farnesoid X receptor-dependent manner. European Journal of Pharmacology 857, pages 172461.
Crossref
Crossref
Omer Shahab, Mehmet Sayiner, James Paik, Sean Felix, Pegah Golabi & Zobair M. Younossi. (2019) Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States. Hepatology Communications 3:3, pages 356-364.
Crossref
Crossref
Mehmet Sayiner, Pegah Golabi, Maria Stepanova, Issah Younossi, Fatema Nader, Andrei Racila & Zobair M. Younossi. (2019) Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. Hepatology 69:1, pages 237-244.
Crossref
Crossref
Nahum Méndez-Sánchez. (2018) Management of primary biliary cholangitis: the importance to identify patients' non-responders to standard treatment. Minerva Medica 109:6.
Crossref
Crossref
Xiao-Long He, Li-Ting Wang, Xiang-Zhong Gu, Jie-Xin Xiao & Wen-Wei Qiu. (2018) A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid. Steroids 140, pages 173-178.
Crossref
Crossref
Peter HegyiJozsef MaléthJulian R. WaltersAlan F. HofmannStephen J. Keely. (2018) Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. Physiological Reviews 98:4, pages 1983-2023.
Crossref
Crossref
Kuo Gai, Yu Huang, Baomin Liu & Yinsheng Zhang. (2018) Synthesis of obeticholic acid, a farnesoid X receptor agonist, and its major metabolites labeled with deuterium. Journal of Labelled Compounds and Radiopharmaceuticals 61:10, pages 799-804.
Crossref
Crossref
Michal Douša, Markéta Slavíková, Tomáš Kubelka, Josef Černý, Petr Gibala & Josef Zezula. (2018) HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control. Journal of Pharmaceutical and Biomedical Analysis 149, pages 214-224.
Crossref
Crossref
Xiaoguang Gao, Ting Fu, Changyuan Wang, Chenqing Ning, Yulong Kong, Zhihao Liu, Huijun Sun, Xiaodong Ma, Kexin Liu & Qiang Meng. (2017) Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury. Biochemical Pharmacology 146, pages 127-138.
Crossref
Crossref
Juan Pablo Arab, Francisco Barrera & Marco Arrese. (2017) Bile Acids and Portal Hypertension. Annals of Hepatology 16, pages S83-S86.
Crossref
Crossref
Atsushi Tanaka, Patrick S.C. Leung, Howard A. Young & M. Eric Gershwin. (2017) Toward solving the etiological mystery of primary biliary cholangitis. Hepatology Communications 1:4, pages 275-287.
Crossref
Crossref
M.G. Fernandez-Barrena, M. Barcena-Varela & J.M. Banales. (2017) New evidence supporting the biliary bicarbonate umbrella theory. Clinics and Research in Hepatology and Gastroenterology 41:2, pages 126-128.
Crossref
Crossref
Sumeyye Samur, Matthew Klebanoff, Reiner Banken, Daniel S. Pratt, Rick Chapman, Daniel A. Ollendorf, Anne M. Loos, Kathleen Corey, Chin Hur & Jagpreet Chhatwal. (2017) Long‐term clinical impact and cost‐effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology 65:3, pages 920-928.
Crossref
Crossref
Lingling Luo, Yin Li, Dongshan Wang, Yuanyuan Zhao, Yahui Wang, Fei Li, Jinan Fang, Hui Chen, Shengjie Fan & Cheng Huang. (2017) Ginkgolide B lowers body weight and ameliorates hepatic steatosis in high-fat diet-induced obese mice correlated with pregnane X receptor activation. RSC Advances 7:60, pages 37858-37866.
Crossref
Crossref